Radiopharmaceuticals Market - By Radioisotope

Radiopharmaceuticals Market – By Source
Radiopharmaceuticals Market – By Type
Radiopharmaceuticals -By Technology / Modality
Radiopharmaceuticals -By Indication
Radiopharmaceuticals- By End User
Radiopharmaceuticals Market – By End User
Radiopharmaceuticals Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radiopharmaceuticals Market Snapshot
Chapter 4. Global Radiopharmaceuticals Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Radioisotope Estimates & Trend Analysis
5.1. By Radioisotope, & Market Share, 2025 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Radioisotope:
5.2.1. Technetium 99
5.2.2. Fluorine 18
5.2.3. Iodine 131
5.2.4. Leutetium 177
5.2.5. Yttrium 90
5.2.6. Gallium 67
5.2.7. Gallium 68
5.2.8. Rubidium 82
5.2.9. Iodine 123
5.2.10. Iodine 125
5.2.11. Indium 111
5.2.12. Other Isotopes
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. By Indication & Market Share, 2025 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Indication:
6.2.1. Oncology
6.2.2. Cardiology
6.2.3. Gastoenterology
6.2.4. Neuroendocrinology
6.2.5. Neurology
6.2.6. Nephrology
6.2.7. Other Indications
Chapter 7. Market Segmentation 3: By Source Estimates & Trend Analysis
7.1. By Source & Market Share, 2025 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Source:
7.2.1. Cyclotrons
7.2.2. Nuclear Reactors
7.2.3. Other Sources
Chapter 8. Market Segmentation 4: By Type Estimates & Trend Analysis
8.1. By Type & Market Share, 2025 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Type:
8.2.1. Diagnostic Radiopharmaceuticals
8.2.2. Therapeutic Radiopharmaceuticals
Chapter 9. Market Segmentation 5: By End-Users Estimates & Trend Analysis
9.1. By End-Users & Market Share, 2025 & 2035
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By End-Users:
9.2.1. Hospitals
9.2.2. Medical Imaging Centers
9.2.3. Cancer Research Institute
9.2.4. Other End Users
Chapter 10. Market Segmentation 6: By Technology / Modality Estimates & Trend Analysis
10.1. By Technology / Modality & Market Share, 2025 & 2035
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Technology / Modality:
10.2.1. SPECT Radiopharmaceuticals
10.2.2. PET Radiopharmaceuticals
10.2.3. Beta-emitting Radiopharmaceuticals
10.2.4. Alpha-emitting Radiopharmaceuticals
Chapter 11. Radiopharmaceuticals Market Segmentation 6: Regional Estimates & Trend Analysis
11.1. North America
11.1.1. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2022 - 2035
11.1.2. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Indication, 2022 - 2035
11.1.3. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Source, 2022 - 2035
11.1.4. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Type, 2022 - 2035
11.1.5. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By End-Users, 2022 - 2035
11.1.6. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Technology / Modality, 2022 - 2035
11.1.7. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By country, 2022 - 2035
11.2. Europe
11.2.1. Europe Radiopharmaceuticals Market revenue (US$ Million) By Radioisotope, 2022 - 2035
11.2.2. Europe Radiopharmaceuticals Market revenue (US$ Million) By Indication, 2022 - 2035
11.2.3. Europe Radiopharmaceuticals Market revenue (US$ Million) By Source, 2022 - 2035
11.2.4. Europe Radiopharmaceuticals Market revenue (US$ Million) By Type, 2022 - 2035
11.2.5. Europe Radiopharmaceuticals Market revenue (US$ Million) By End-Users, 2022 - 2035
11.2.6. Europe Radiopharmaceuticals Market revenue (US$ Million) By Technology / Modality, 2022 - 2035
11.2.7. Europe Radiopharmaceuticals Market revenue (US$ Million) by country, 2022 - 2035
11.3. Asia Pacific
11.3.1. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Radioisotope, 2022 - 2035
11.3.2. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Indication, 2022 - 2035
11.3.3. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Source, 2022 - 2035
11.3.4. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Type, 2022 - 2035
11.3.5. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By End-Users, 2022 - 2035
11.3.6. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Technology / Modality, 2022 - 2035
11.3.7. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) by country, 2022 - 2035
11.4. Latin America
11.4.1. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Radioisotope, (US$ Million) 2022 - 2035
11.4.2. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Indication, (US$ Million) 2022 - 2035
11.4.3. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Source, (US$ Million) 2022 - 2035
11.4.4. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Type, (US$ Million) 2022 - 2035
11.4.5. Latin America Radiopharmaceuticals Market revenue (US$ Million) By End-Users, (US$ Million) 2022 - 2035
11.4.6. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Technology / Modality, 2022 - 2035
11.4.7. Latin America Radiopharmaceuticals Market revenue (US$ Million) by country, 2022 - 2035
11.5. Middle East & Africa
11.5.1. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By Radioisotope, (US$ Million) 2022 - 2035
11.5.2. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By Indication, (US$ Million) 2022 - 2035
11.5.3. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By Source, (US$ Million) 2022 - 2035
11.5.4. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By Type, (US$ Million) 2022 - 2035
11.5.5. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By End-Users, (US$ Million) 2022 - 2035
11.5.6. Middle East a& Africa Radiopharmaceuticals Market revenue (US$ Million) By Technology / Modality, 2022 - 2035
11.5.7. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) by country, 2022 - 2035
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Novartis AG
12.2.2. Curium SAS
12.2.3. Bayer AG
12.2.4. Telix Pharmaceuticals Limited
12.2.5. Lantheus Holdings, Inc.
12.2.6. GE HealthCare Technologies Inc.
12.2.7. Cardinal Health, Inc.
12.2.8. Jubilant Pharmova Limited
12.2.9. ITM Isotope Technologies Munich SE
12.2.10. Eli Lilly and Company
12.2.11. AstraZeneca PLC
12.2.12. PharmaLogic Holdings Corp.
12.2.13. Life Molecular Imaging GmbH
12.2.14. Bracco Imaging S.p.A.
12.2.15. Siemens Healthineers AG
12.2.16. Eckert & Ziegler Strahlen- und Medizintechnik AG
12.2.17. NorthStar Medical Radioisotopes, LLC
12.2.18. Nusano, Inc.
12.2.19. Nordion (Canada) Inc.
12.2.20. IBA RadioPharma Solutions (Ion Beam Applications S.A.)
12.2.21. ANSTO
12.2.22. Yantai Dongcheng Pharmaceutical Group Co., Ltd.
12.2.23. Others
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.